Zofran Cases Centralized

Publish Date : 11/06/2015

On October 18^th, the Judicial Panel on Multidistrict Litigation ordered that all pending Zofran cases be consolidated in the U.S. District Court for the District of Massachusetts. This is a victory for all parents whose children have been harmed by Zofran.

Zofran is an anti-nausea drug that was introduced by GlaxoSmithKline in 1991. Although the drug is not FDA approved for use in pregnant women, approximately one million women are prescribed Zofran each year to help them cope with morning sickness. This type of use, known as “off-label,” is not illegal, but it can mean that the drug presents risks that are not fully understood.

Zofran may be linked to birth defects

Unfortunately, it appears that Zofran use during pregnancy may lead to serious brith defects. Since the drug was released in 1991, the FDA has received hundreds of reports of birth defects in children born to women who took Zofran while pregnant. Data about whether Zofran causes birth defects is still inconclusive, but several studies have shown a correlation between use of the drug and an increased risk for birth defects.

In response to the possible link between Zofran and birth defects, many families across the country have filed suit against GlaxoSmithKline in order to seek answers and receive compensation for the harm that they have suffered. Because so many people have sued GlaxoSmithKline for the same issue, the Judicial Panel on Multidistrict Litigation ordered that all Zofran cases be placed into a single MDL. An MDL gathers up all of the cases from around the country on a single issue and places them in front of one judge. This saves plaintiffs time and money by speeding up the process and eliminating redundant and wasteful discovery.

If you or a loved one has been injured by Zofran, now is the time to act. The attorneys at McSweeney / Langevin are experienced lawyers who focus their practice on dangerous drug and defective device cases. Give us a call. We can help. 1-877-542-4646